Atara biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 45,040 restricted stock units of atara's common stock to nine newly hired employees and stock options to purchase an aggregate of 39,978 shares of atara's common stock to three such newly hired
ATRA Ratings Summary
ATRA Quant Ranking